Political

U.S. biotech pricing and reimbursement policy remains a sector-wide overhang, but COYA’s rare-disease focus can be somewhat less exposed than larger peers with broader commercial portfolios.

FDA and other regulator scrutiny on clinical endpoints and accelerated-approval pathways affects all development-stage biotech similarly, leaving COYA broadly in line with peers on approval risk.

Cross-border trial and supply-chain geopolitics can disrupt development timelines across the sector, but COYA’s small footprint limits absolute exposure versus globally distributed peers.

Public funding and orphan-drug incentives support rare-disease development across the industry, yet COYA does not appear to have a unique policy advantage over comparable peers.

Economic

Higher-for-longer capital costs and tighter biotech financing conditions pressure all pre-revenue developers, and COYA’s small market capitalization makes it more dependent on external funding than profitable peers.

Investor risk appetite for speculative biotech remains cyclical, so COYA’s external funding environment is broadly similar to other micro-cap development-stage names.

Inflation in clinical trial services and specialized labor raises industry costs, but COYA faces the same vendor-price inflation as peers rather than a distinct macro advantage.

Absence of meaningful current revenue leaves COYA more exposed to macro funding windows than commercial-stage peers, but this is typical for its cohort.

Social

Aging populations and higher prevalence of chronic neurodegenerative disease support long-run demand for rare-disease therapies, benefiting COYA alongside peers in the same therapeutic area.

Greater patient and caregiver awareness of rare-disease treatment options improves diagnosis and referral rates across the category, which is favorable for COYA versus non-rare-disease biotech peers.

Orphan-disease communities often show strong advocacy and trial participation, creating a supportive demand backdrop that is structurally better than for many broader-indication peers.

The social value placed on therapies for high-unmet-need diseases tends to sustain payer and public interest, giving COYA a modest positioning tailwind versus generalist biotech peers.

Technological

Advances in biomarker-driven development and precision medicine support rare-disease programs industry-wide, but COYA does not appear to have a clearly differentiated external technology tailwind versus peers.

Improved trial design, digital recruitment, and decentralized-study tools can reduce development friction across biotech, yet these benefits are broadly available to comparable peers.

Manufacturing and formulation innovations in biologics and cell-based therapies may help the sector, but COYA’s relative benefit versus peers depends on platform fit rather than the external environment alone.

Rapid scientific progress in neurodegeneration expands the addressable research field, though it also raises the bar for differentiation across all peers.

Legal

Orphan-drug exclusivity and related regulatory incentives improve the legal-commercial backdrop for rare-disease developers, giving COYA a better framework than many non-orphan peers.

FDA clinical, safety, and labeling requirements remain stringent for all development-stage biotech, so COYA’s legal positioning is not materially better than comparable peers on approval risk.

Patent and IP protection are critical in biotech and generally support value creation, but COYA faces the same litigation and freedom-to-operate environment as peers.

Healthcare compliance and anti-kickback rules are less burdensome for a pre-commercial developer than for marketed-product peers, modestly improving COYA’s relative legal positioning.

Environmental

Environmental regulation mainly affects biotech through lab, waste, and manufacturing compliance, which is a sector-wide cost rather than a clear relative advantage for COYA.

Climate-related supply-chain disruptions can affect clinical materials and logistics across the industry, but COYA’s smaller operating footprint limits absolute exposure versus larger peers.

Sustainability expectations from investors and partners are rising, yet they are broadly applied across biotech and do not create a distinct external edge for COYA.

Environmental permitting and facility standards matter more for scaled manufacturing peers, leaving COYA roughly neutral on this factor versus other development-stage companies.

Overall Score

COYA’s external positioning is mixed, with a favorable rare-disease demand backdrop and orphan-drug incentives offset by weak macro funding conditions typical of pre-revenue biotech.

Score Driver: Rare-Disease And Orphan-Drug Tailwinds Versus Peers